1. Introduction
Menopause has a negative impact on quality of life (QoL), with a gradual decrease from the premenopausal period to the postmenopausal period [1], in terms of both physical and mental health [2,3]. Such decrease in the QoL of postmenopausal women is associated with the appearance of genitourinary [4,5,6] and, especially, vasomotor [1] symptoms, such as hot flushes [7]. Moreover, in many cases, other psychological factors appear together during the postmenopausal period, such as depression, which worsen the perception toward QoL [8].
The consumption of chocolate, especially dark chocolate, has been associated with small, yet beneficial changes in the cardiovascular health of postmenopausal women [9]. However, very few studies have analysed its relationship with mental health and/or components of QoL. Balboa-Castillo et al. [10] analysed a cohort of 4599 individuals (average age: 54.1 years, 50.8% women), with no evidence of correlation between QoL and a greater or lower consumption of 10 g/day of chocolate, although these authors did not include an analysis based on age and sex. In women, the consumption of chocolate could have a significant positive impact on sexual function, especially on sexual desire [11]. A greater consumption of chocolate has been associated with a higher score in the Centre for Epidemiologic Studies Depression Scale (CES-D) [12], in which 16 or more points often represent a positive screening result, although no cause–effect relationship has been established between showing more signs of depression and a greater consumption of chocolate [13].
The benefits of dark chocolate have been attributed to a type of polyphenols known as flavonoids, which include flavonols and other polyphenols, such as epicatechin and catechin. In this line, some studies [14] have related the consumption of certain flavonol- and polyphenol-rich products, such as propolis [15], fruits and vegetables [16], to QoL, with rather inconclusive results. In women, the habitual consumption of coffee has been associated with slight improvement in the mental dimension of QoL [17]. Similarly, in postmenopausal women, the consumption of fermented soy has been related to an improvement in QoL [18], whereas the Mediterranean diet, which includes a large variety of polyphenol-rich products, has not been clearly associated with an improvement in QoL in older adults [19].
To sum up, despite the worsening of QoL that takes place during menopause and the indications about the possible positive effect that the consumption of chocolate can have on such deterioration, there are very few studies that approached this topic, obtaining divergent and poorly clarifying results [10,11,13]. Beyond the evaluation of pharmacological and/or nutritional therapies during menopause, it is fundamental to determine the real impact of these on QoL [20].
This study aimed to assess the effect of adding 10 g per day of chocolate with a high concentration of cocoa (99%) to the habitual diet, for 6 months, on QoL, in a sample of postmenopausal women. 2. Materials and Methods 2.1. Design and Setting
This is a controlled, randomised clinical trial with two parallel groups. The participants were recruited in the doctor offices of four urban primary care centres of Salamanca (Spain) through consecutive sampling. The evaluation period was from June 2018 to August 2019. It was conducted in the Primary Care Research Unit of Salamanca (APISAL), which is part of the Spanish Research Network for Preventive Activities and Health Promotion in Primary Care (redIAPP) and the Institute of Biomedical Research of Salamanca (IBSAL). The clinical trial has been registered in clinicaltrials.gov as NCT03492983. The protocol of the trial has been published [21].
This manuscript presents results on quality of life as a secondary outcome from the clinical trial. Results on blood pressure, as the main outcome of the trial [22], as well as results on body composition, as a secondary outcome [23], have been previously published.
2.2. Study Participants The study included 140 women aged 50–64 years in the postmenopausal period, defined as amenorrhea for at least 12 consecutive months. The exclusion criteria were: personal history of cardiovascular disease, diabetes mellitus, arterial hypertension or dyslipidaemia under pharmacological treatment, hypocaloric diets, clinically demonstrable neurological and/or neuropsychological disease, hormone replacement therapy, habitual consumption of over 210 g per week (g/week) of cocoa and intolerance and/or allergic reaction to cocoa or any of components of the supplement. 2.3. Sample Size
Sample size estimation was carried out considering the change in arterial systolic pressure as the main variable of this clinical trial. To detect a minimum difference of 2.9 mm Hg in systolic arterial pressure between the two groups, 140 participants were required (70 per group), assuming an alpha risk of 0.05, a beta risk of 0.20 in a two-sided contrast and a standard deviation (SD) of 5.8 mm Hg. A follow-up loss rate of 10% was also assumed. These calculations were based on the results obtained in a similar study that reported a decrease of 6.5 ± 5.8 mm Hg in systolic arterial pressure [24]. With the 140 participants included in this study, we obtained a power of 72% for the hypothesis test to detect a statistically significant difference of 6 points in the mean score of the EuroQol Visual Analogue Scale (EQ-VAS) between study groups, assuming an alpha risk of 0.05 in a two-sided contrast.
2.4. Procedures and Randomisation
The study variables were measured in all participants at baseline and at 6-month follow-up (Figure 1). The women in the intervention group paid another 5 visits for chocolate resupply at 1, 2, 3, 4 and 5 months after the baseline visit. In these resupply visits, held in the health centre, no other procedure was carried out, except for the supply of the necessary chocolate until the next visit and the gathering of a calendar with the record of the chocolate intakes performed.
Participants were randomised into two groups: intervention group (IG) and control group (CG). The randomisation sequence was carried out by an independent researcher using the Epidat 4.2 software [25]. Depending on the order of the baseline visit, participants received their randomisation number, which was hidden until all the women were assigned to a group. To ensure the blinding, the participants were clearly requested not to reveal their group to the blinded researchers during the interviews.
The characteristics of the intervention impeded the blinding of the participants. With the aim of minimising contamination between groups, the evaluation and chocolate resupply visits in the IG were conducted by different researchers. The information related to the randomisation of the treatment was kept in a safe in case of emergency unblinding. 2.5. Intervention Participants in the CG did not receive any intervention, while participants in the IG were supplied with cocoa-rich chocolate (99%) and were instructed to consume 10 g daily of this supplement added to their habitual food intake. The intervention period was 6 months. During the first supply visit, the IG participants were provided with instructions about the consumption and storage of the chocolate supplement, recommending them to take the daily dose at the same time of the day. Additionally, women in the IG were asked to record the time of each daily intake in a calendar provided by the researchers, which was returned to them at each resupply visit. The daily nutritional contribution of 10 g of this chocolate is 59 kcal, 0.8 g of carbohydrates, 1.5 g of protein and 5.1 g of fat, of which 3.1 g correspond to saturated fat. The contribution of polyphenols per 10 g of this product is 65.4 mg. All participants were asked to continue with their usual dietary pattern without modifying their eating habits during the study period. 2.6. Main Outcomes Quality of life (QoL) was evaluated using two tools: the 3-level version of EuroQol-5D (EuroQoL-5D-3L) and the Cervantes scale.
EuroQol [26,27] is a health state measurement that includes two tools: the EuroQol-5D (EQ-5D) and the EuroQol Visual Analogue Scale (EQ-VAS). In the present study, the 3-level version of EQ-5D (EQ-5D-3L) was used, which descriptively analyses five dimensions (mobility, self-care, usual activities, pain and discomfort and anxiety and depression) on a scale of three possible answers categorised from 1 to 3 (1 “I have no problems”, 2 “I have some problems”, 3 “I have serious problems”). The results are presented through a descriptive analysis of each of the five dimensions and through the estimation of a general health state index between 0 (worst health state) and 1 (best health state) [28]. This EQ-5D summary index is derived by applying a formula that essentially attaches values (weights) to each of the levels in each dimension. The index can be calculated by deducting the appropriate weight from 1, the value for full health.
The EQ-VAS is a visual analogue scale that evaluates the general health state perceived by each individual. The range of this scale is between 0 (very bad health state) and 100 (optimal health state).
The Cervantes scale [29] was specifically designed for postmenopausal women. It assesses the impact of menopause on different physical and psychosocial characteristics and, especially, its effect on general wellbeing. It consists of 31 items structured in 4 dimensions: menopause and health, sexuality, mental domain and relationship. Furthermore, the dimension “menopause and health” includes three subdimensions: vasomotor symptoms, health and ageing. Regarding the global score of the scale, the highest score is 155 points, which represents low QoL, whereas the lowest score is 0 points, which represents the best QoL possible. All dimensions and subdimensions have a similar score range, where the lowest value indicates the best QoL and the highest value indicates the worst QoL.
2.7. Other Measurements
During the baseline evaluation, information about the clinical and sociodemographic variables was gathered. This information included the marital status, the education level and the time elapsed from the onset of menopause. Moreover, the history of the following morbidities was also recorded: gestational diabetes, hypertension and dyslipidaemia without pharmacological treatment and diagnosed depression. A more detailed description of the methodology and of the assessment of other variables, such as physical activity, alcohol consumption and smoking, is included in the trial protocol [21].
2.8. Data Collection Procedure, Data Management and Monitoring The data collection in the evaluation visits was conducted by a previously trained nurse: this person was not the researcher in charge of making the randomisation and later analysis of the data. A unique identification code was used for every participant of the study in order to identify the data recorded in each measurement. Thus, a database was created, which could only be accessed by the professionals who worked in the study. 2.9. Ethical Considerations The study was approved by the Clinical Research Ethics Committee of the Salamanca Health Area (‘CREC of the Health Area of Salamanca’) in February 2018 (ethic approval code: PI11812/2017). Informed consent was provided by each participant in accordance with the Declaration of Helsinki. All participants received information on the objectives of the project and the risks and benefits of the explorations to be conducted. The confidentiality of the participants’ data was guaranteed at all times in accordance with the provisions of Organic Law 3/2018, of 5 December, on Personal Data Protection and digital rights, and European Regulation 2016/679 of the European Parliament and of the Council of 27 April 2016 on General Data Protection (GDPR), and under the conditions established by Spanish Law 14/2007 on biomedical research. 2.10. Statistical Analyses
The statistical analyses were performed according to the study protocol [21]. The data were checked for normal distribution and most of the data were considered normally distributed. The characteristics of the study population are presented as mean and standard deviation (SD) or median (interquartile range) for the continuous variables and as frequency distribution for the qualitative variables. To evaluate the comparability in the baseline evaluation between the two groups, the chi-square test and Fisher’s exact test were used for the qualitative variables. In addition, a Student’s t-test and Mann–Whitney U test were applied to compare the mean values between groups. The effect of chocolate consumption on the main variables of QoL was analysed through an analysis of covariance (ANCOVA), adjusted for the main determinants of QoL gathered in the interviews: age, education level, marital status, time elapsed since the beginning of menopause, daily calorie intake (kcal), baseline consumption of chocolate with 70% cocoa, physical activity, alcohol consumption, smoking, depression and untreated dyslipidaemia. The results of these analyses are presented as estimated marginal mean and its 95% confidence interval (CI). The change in each group was analysed using a Student’s t-test for paired data. To address the possible bias due to a lack of response in some items of the Cervantes scale, we applied the multiple imputation by chained equations with 50 sets of data imputed to the results and covariables [30,31]. The estimations of each set of imputed data were combined following the guidelines described by Rubin [32]. An alpha risk of 0.05 was established as the limit of statistical significance. All analyses were performed using SPSS V.23.0 (IBM Corp, Armonk, NY, USA).
3. Results 3.1. Baseline Characteristics of the Study Participants
A total of 140 women (IG: n = 73, CG: n = 67) were included in this study. Three participants were lost in the evaluation at 6 months from the beginning of the study (IG: n = 2, CG: n = 1). The two losses in IG corresponded to two women who were diagnosed with cancer under pharmacological treatment during the study period, whereas the one from CG was a woman who decided to abandon the study in the follow-up visit (Figure 1). At baseline, no differences were found in any of the clinical or sociodemographic variables analysed (age, marital status or education level), nor in the time elapsed from the beginning of menopause. The baseline consumption of chocolate (g/week) was similar in both groups, as well as the rest of the analysed lifestyles: smoking, alcohol consumption, daily calorie intake and physical activity. Similarly, no differences were found in the baseline evaluation in terms of the number and percentage of women with a history of gestational diabetes, depression, untreated dyslipidaemia or hypertension (Table 1). Daily energy intake and nutrients of habitual diet, as well as chocolate intake, remained unchanged during the intervention in both groups.
3.2. Changes in QoL Measured with EuroQol
A descriptive analysis of the five dimensions evaluated in the EQ-5D-3L (mobility, self-care, usual activities, anxiety/depression and pain/discomfort) both in the baseline evaluation and at the 6-month evaluation visit is shown in Table 2. No differences were observed in the baseline evaluation between the groups in any of the dimensions.
In a model adjusted for the main determinants of QoL, the group that consumed 10 g of cocoa-rich chocolate daily showed a non-significant increase of 0.044 in the EQ-5D-3L score (95% CI: −0.012, 0.099) (p = 0.125), with respect to the CG. Moreover, the results of the EQ-VAS showed an increase of 6.0 (95% CI: 0.4, 11.7) in favour of the intervention group (p = 0.036) (Table 3).
3.3. Changes in QoL Measured with the Cervantes Scale
Using the same ANCOVA model adjusted for the main determinants of QoL considered in this study, no significant changes were observed in the global score of QoL evaluated with the Cervantes scale (1.1 points; 95% CI: −4.5, 6.7; p = 0.478). Similarly, no changes were found when analysing menopause and health, mental domain, sexual relations and relationship; likewise, the subdimensions of vasomotor symptoms, health and ageing did not show any significant differences (Table 4).
4. Discussion The results of this clinical trial show that, in a sample of postmenopausal women, the daily consumption of 10 g of cocoa-rich chocolate produced a slight improvement in the score of the visual analogue scale of the EuroQol questionnaire (EQ-VAS), although there were no changes in the global score of QoL evaluated with the general questionnaire (EuroQoL-5D) or with a specific questionnaire for this population (Cervantes scale). Similarly, there were no changes in the dimensions or subdimensions analysed in the latter: menopause and health, mental domain, sexual relations, relationship, vasomotor symptoms, health and ageing.
The main tool used for the evaluation of health-related QoL in this study was the EuroQoL questionnaire. Within this questionnaire, there are two clearly differentiated sections with different purposes and objectives. The profile of the EQ-5D was developed to describe, in a quick and simple manner, the dimensions of health-related QoL (mobility, self-care, usual activities, pain and discomfort, anxiety and depression), as well as to estimate a single value that summarises all of these dimensions [26]. On the other hand, the EQ-VAS is aimed at obtaining the general health state of the participant, providing important and complementary information about the opinions of the patients regarding their own health. In a trial conducted in older individuals, an improvement in QoL measured with the EQ-5D was observed in the group that received a natural beverage made of flavonoid-rich cocoa powder, with a significant decrease in their perception toward problems in mobility and pain/discomfort, and without changes in the rest of the dimensions [33]. In our study, the proportion of women in each of the categories of the dimensions analysed in the EQ-5D-3L remained similar after the intervention. However, there were differences in the values of the EQ-VAS. The intake of chocolate is anecdotally associated with an increase of happiness, although few experimental studies have analysed this effect. Its sensory characteristics, nutritional composition and the presence of psychoactive components, such as tyramine and theobromine, have been suggested as the agents that cause the effects of chocolate on mental health and mood [34]. Another study revealed that chocolate seems to increase positive mood, particularly when eaten mindfully [35]. The EQ-VAS comprises all the aspects of health-related QoL and not only the content of the five dimensions measured in the EQ-5D. Therefore, the differences observed in the results of the EQ-VAS could help to value the general health status in further agreement with the perspective of the patient [36]. The results of the effect of a controlled and moderate dose of chocolate (10 g daily) in postmenopausal women observed in our study could be consistent with the effect attributed to chocolate on mood. The amount of 10 g of chocolate used in the intervention taken every day complies with the recommendations of the European Food Safety Authority [37] to maintain endothelium-dependent vasodilation [37], which is relevant since the main outcome of the trial that this study is part of was blood pressure, and Nurk et al. [38], who highlighted the attainment of a maximal beneficial effect on mental health with this daily amount of such product. Furthermore, it was reported that consumption of 14 g of milk chocolate enhanced positive mood [35]. Though the product used in this trial was dark chocolate, which is known to contain higher quantity of cocoa than milk chocolate, and the consumption of a similar amount of it was expected to have a greater effect on quality of life, it may not be sufficient to show changes in this outcome.
No changes were detected in the different dimensions of QoL evaluated with the Cervantes scale. This scale, validated in a Spanish population of perimenopausal women of 45–64 years of age [29], has been used in some studies [39,40]. The consumption of chocolate (including dark chocolate, milk chocolate and white chocolate) as a baseline condition in the study groups was 68 g/week (median (interquartile range): 42 (9–109) g/week in the IG and 50 (21–80) g/week in the CG), and this consumption was not restricted during the study. Therefore, the aim was to analyse whether an additional contribution of 10 g/day of dark chocolate improved the study variables. This was a condition of the design that could partly justify the absence of additional beneficial results on the dimensions of the Cervantes scale, especially on sexuality. In previous studies, the consumption of chocolate had a significant impact on sexual desire in women [11], although after adjusting for age, such association disappeared. However, it is necessary to further investigate the impact of the intake of chocolate on specific aspects of QoL.
Although it was slight, the change found in the score of the EQ-VAS in favour of the experimental group, which received the additional amount of dark chocolate, could reflect a better perception toward the general health state after the intervention. Considering the clinical context posed by a decrease of QoL after menopause, those interventions, especially the non-pharmacological ones, which can improve the health state could be clinically relevant. This is especially important in people over 60 years of age, in whom the changes in QoL are considered as potential predictors of mortality [41].
Chocolate is a natural source of caffeine. The amount of this component present in chocolate varies depending on the percentage of cocoa it contains [42]. Caffeine has multiple effects on health, some of which could affect quality of life. Among the effects exerted by caffeine, it has to be highlighted its potential vasoconstricting and anti-inflammatory effects, which can have a positive influence on pain relief [42]. Moreover, the benefits of chocolate on mood seem to be mainly exerted by caffeine [43]. Also, caffeine consumption could reduce sleep quality [44], which has been shown to be associated with hot flashes, loss of sexual interest and depressed mood [45], having a negative impact on quality of life. Nonetheless, our results did not show any significant change in these domains, and none of the questionnaires used explore sleep quality as a component of quality of life.
Modifications in the dietary pattern and eating habits usually followed by participants could have possibly altered the results, hence all subjects were asked to not modify these during the study period. Results showed that daily energy intake, nutrients of habitual diet and chocolate intake remained unchanged in both the IG and CG, which suggests that these parameters were not altered during the intervention.
Another point to discuss is the mean time from menopause onset, which was 6.9 years in both study groups. This has to be considered, as many of the physiological changes during menopause take place during the period of menopausal transition. Avis et al. observed that the duration of vasomotor symptoms was more than 7 years during the menopausal transition for more than half of the participants in the Study of Women’s Health Across the Nation (SWAN), and persisted for 4.5 years after the final menstrual period [46]. These vasomotor symptoms are associated with poorer quality of life, negative mood and sleep problems [47]. Considering this, carrying out this trial earlier in the menopause period could have had a greater impact on quality on life and should be taken into account in future research.
There are some limitations that must be highlighted. Firstly, the design of the trial that this study is part of does not establish the improvement of QoL as the main objective, and it is taken as a secondary variable. Thus, the sample size could be insufficient for the contrast of this variable. Secondly, there was no blinding in the participants due to the nature of the intervention, which may have influenced the findings about QoL. The participants of the study had no restrictions on the consumption of cocoa or chocolate in terms of presentation, which may underestimate the effect of the intervention; however, this approach is more in line with the eating habits of the population. Another limitation could be the lack of control of polyphenol intake during the intervention. This was not possible since the tool used to assess the nutritional composition of the habitual diet does not provide data on the polyphenol content of the diet or the specific foods consumed. We could assume that randomisation had balanced the groups with respect to dietary intake as well as polyphenol intake; nonetheless, this should be considered in future studies. 5. Conclusions We can conclude that the additional daily contribution of 10 g of cocoa-rich chocolate in postmenopausal women could have a slight impact on their perception toward their health state, although without modifying the health-related QoL or the dimensions that compose it. Despite this, further analytical studies are required to delve specifically into these associations.
| Intervention Group (n = 73) | Control Group (n = 67) | |
|---|---|---|
| Age, years | 57.1 ± 3.5 | 57.5 ± 3.8 |
| Marital status, n (%) | ||
| Married/cohabitant | 48 (65.8) | 47 (70.1) |
| Separated/divorced | 8 (11.0) | 7 (10.4) |
| Single | 15 (20.5) | 9 (13.4) |
| Widowed | 2 (2.7) | 4 (6.0) |
| Education level, n (%) | ||
| Elementary education | 16 (21.9) | 12 (17.9) |
| Middle–High school | 22 (30.1) | 29 (43.3) |
| Bachelor | 17 (23.3) | 11 (16.4) |
| Postgraduate | 18 (24.7) | 15 (22.4) |
| Time from menopause onset, years | 6.9 ± 4.6 | 6.9 ± 3.6 |
| Chocolate intake, g/week | 42 (9–109) | 50 (21–80) |
| >70% cocoa chocolate intake, g/week | 0 (0–26) | 0 (0–24) |
| Lifestyles | ||
| Smokers, n (%) | 12 (16.4) | 9 (13.4) |
| Adequate alcohol consumption, n (%) | 71 (97.3) | 65 (97.0) |
| Physical activity light intensity, MET h/week | 18.5 ± 9.4 | 18.8 ± 11.3 |
| Energy, kcal/day | 1720 ± 357 | 1780 ± 402 |
| Morbidities, n (%) | ||
| Untreated dyslipidaemia | 8 (11.0) | 10 (14.9) |
| Untreated hypertension | 1 (1.4) | 0 (0) |
| Gestational diabetes | 3 (4.1) | 1 (1.5) |
| Depression | 15 (20.5) | 15 (22.4) |
Values expressed as mean ± standard deviation, median (interquartile range) or frequencies. Abbreviations: MET, metabolic equivalent of task.
| Intervention Group (n = 71) | Control Group (n = 66) | |||
|---|---|---|---|---|
| Baseline | 6 Months | Baseline | 6 Months | |
| Mobility, n (%) | ||||
| No problems in walking about | 65 (91.5) | 69 (97.2) | 62 (93.9) | 60 (90.9) |
| Some problems in walking about | 6 (8.5) | 2 (2.8) | 4 (6.1) | 6 (9.1) |
| Confined to bed | - | - | - | - |
| Self-care, n (%) | ||||
| No problems with self-care | 71 (100) | 71 (100) | 66 (100) | 66 (100) |
| Some problems washing or dressing herself | - | - | - | - |
| Unable to wash or dress herself | - | - | - | - |
| Usual activities, n (%) | ||||
| No problems with performing her usual activities | 66 (93.0) | 69 (97.2) | 65 (98.5) | 63 (95.5) |
| Some problems with performing her usual activities | 5 (7.0) | 2 (2.8) | 1 (1.5) | 3 (4.5) |
| Unable to perform her usual activities | - | - | - | - |
| Anxiety and depression, n (%) | ||||
| Not anxious or depressed | 51 (71.8) | 55 (77.4) | 57 (86.4) | 59 (89.4) |
| Moderately anxious or depressed | 19 (26.8) | 15 (21.1) | 9 (13.6) | 7 (10.6) |
| Extremely anxious or depressed | 1 (1.4) | 1 (1.4) | - | - |
| Pain and discomfort, n (%) | ||||
| No pain or discomfort | 46 (64.8) | 52 (73.2) | 50 (75.8) | 46 (69.7) |
| Moderate pain or discomfort | 23 (32.4) | 19 (26.8) | 15 (22.7) | 20 (30.3) |
| Extreme pain or discomfort | 2 (2.8) | - | 1 (1.5) | - |
Abbreviations: EQ-5D-3L, 3-level version of EQ-5D.
| Intervention Group (n = 71) | Control Group (n = 66) | |||||
|---|---|---|---|---|---|---|
| Baseline | 6 Months | Baseline | 6 Months | Adjusted Intergroup Difference (IG-CG) 1 | p | |
| EQ-5D-3L 2,3 | 0.868 ± 0.159 | 0.901 ± 0.123 | 0.919 ± 0.124 | 0.907 ± 0.124 | 0.044 (−0.012, 0.099) | 0.125 |
| EQ-VAS 4 | 74.7 ± 13.9 | 78.1 ± 14.0 | 78.3 ± 13.6 | 77.2 ± 14.9 | 6.0 (0.4, 11.7) | 0.036 |
Values expressed as mean ± standard deviation. Abbreviations: EQ-5D-3L, 3-level version of EQ-5D; EQ-VAS, EuroQoL visual analogue scale. 1 These values are adjusted for age, education level, marital status, time elapsed since the beginning of menopause, daily calorie intake (kcal), baseline consumption of chocolate with 70% cocoa, physical activity, alcohol consumption, smoking, depression and untreated dyslipidaemia. Results are based on analysis of covariance (ANCOVA). 2 Difference between groups at baseline (p < 0.05). 3 Range between 0 (worst quality of life) and 1 (best quality of life). 4 Range between 0 (worst quality of life) and 100 (best quality of life).
| Intervention Group (IG) (n = 71) | Control Group (CG) (n = 66) | |||||
|---|---|---|---|---|---|---|
| Baseline | 6 Months | Baseline | 6 Months | Adjusted Intergroup Difference (IG–CG) 1 | p | |
| Total score (0–155) 2 | 51.8 (2.5) | 52.0 (2.4) | 48.5 (2.4) | 47.4 (2.5) | 1.1 (−4.5, 6.7) | 0.478 |
| Dimensions | ||||||
| Menopause and health (0–75) | 26.2 (1.5) | 26.1 (1.4) | 24.9 (1.4) | 24.9 (1.3) | 0.1 (−2.8, 3.2) | 0.927 |
| Vasomotor symptoms (0–15) | 6.8 (0.6) | 6.5 (0.5) | 6.3 (0.6) | 5.7 (0.5) | 0.3 (−0.8, 1.4) | 0.622 |
| Health (0–25) | 7.7 (0.6) | 8.0 (0.6) | 7.8 (0.5) | 7.8 (0.5) | 0.3 (−1.0, 1.6) | 0.652 |
| Ageing (0–35) | 11.7 (0.7) | 11.6 (0.6) | 10.8 (0.7) | 11.3 (0.7) | −0.6 (−2.1, 0.9) | 0.431 |
| Mental domain (0–45) | 8.5 (0.9) | 9.6 (0.9) | 8.2 (0.7) | 8.3 (0.9) | 1.0 (−1.1, 3.0) | 0.357 |
| Sexuality (0–20) | 11.4 (0.5) | 10.7 (0.6) | 11.2 (0.6) | 10.2 (0.6) | 0.2 (−1.5, 1.8) | 0.848 |
| Relationship (0–15) | 5.7 (0.6) | 5.7 (0.6) | 4.7 (0.6) | 4.3 (0.6) | −0.2 (−1.5, 1.1) | 0.775 |
Values expressed as mean (standard error) and differences are means (95% confidence interval). 1 These values are adjusted for age, education level, marital status, time elapsed since the beginning of menopause, daily calorie intake (kcal), baseline consumption of chocolate with 70% cocoa, physical activity, alcohol consumption, smoking, depression and untreated dyslipidaemia. Results are based on analysis of covariance (ANCOVA). 2 Range between 0 (best quality of life) and 155 (worst quality of life).
Author Contributions
Conceptualization, J.I.R.-R., J.A.M.-F., L.G.-O. and I.A.G.-Y.; methodology, L.G.-O., J.I.R.-R., J.A.M.-F. and I.A.G.-Y.; validation, M.A.G.-M. and E.R.-S.; formal analysis, J.I.R.-R., J.A.M.-F. and I.A.G.-Y.; investigation, M.A.G.-M., E.R.-S. and O.T.-M.; resources, O.T.-M.; data curation, E.R.-S. and O.T.-M.; writing-original draft preparation, I.A.G.-Y. and J.I.R.-R.; writing-review and editing, L.G.-O., M.A.G.-M., E.R.-S., O.T.-M. and J.A.M.-F.; supervision, J.I.R.-R., J.A.M.-F. and L.G.-O.; project administration, J.I.R.-R., J.A.M.-F. and I.A.G.-Y.; funding acquisition, J.A.M.-F. and J.I.R.-R. All authors have read and agreed to the published version of the manuscript.
Funding
This study was supported in part by grants funded by Gerencia Regional de Salud de Castilla y León (GRS 1583/B/17). It was also supported by the Instituto de Salud Carlos III of the Ministerio de Ciencia e Innovación (Spain) through the Red de Investigación en Actividades Preventivas y Promoción de la Salud (redIAPP, RD16/0007), co-financed with the European Union's ERDF.
Acknowledgments
The authors are grateful to all the volunteers for their participation, and the professionals involved in the study: José I Recio-Rodríguez, José A Maderuelo-Fernández, Luis García-Ortiz, Manuel A Gómez-Marcos, Irene A García-Yu, Rosario Alonso-Domínguez, Sara Mora-Simón, Natalia Sánchez-Aguadero, Jesús González-Sánchez, Cristina Agudo-Conde, Cristina Lugones-Sánchez, Benigna Sánchez-Salgado, Carmen Castaño-Sánchez, Emiliano Rodríguez-Sánchez, Susana González-Manzano, Olaya Tamayo-Morales and Susana González-Sánchez.
Conflicts of Interest
The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. Lindt and Sprüngli provided the necessary chocolate for the implementation of the study. This company did not play any role in the design of the study, the data analysis, the reporting of results, or the decision to present the manuscript for publication.
1. Sun, N.; Xing, J.; Li, L.; Han, X.-Y.; Man, J.; Wang, H.-Y.; Lv, D.-M. Impact of Menopause on Quality of Life in Community-based Women in China: 1 Year Follow-up. Arch. Psychiatr. Nurs. 2018, 32, 224-228.
2. Hess, R.; Thurston, R.C.; Hays, R.D.; Chang, C.-C.H.; Dillon, S.N.; Ness, R.B.; Bryce, C.L.; Kapoor, W.N.; Matthews, K.A. The impact of menopause on health-related quality of life: Results from the STRIDE longitudinal study. Qual. Life Res. 2012, 21, 535-544.
3. Liu, K.; He, L.; Tang, X.; Wang, J.; Li, N.; Wu, Y.; Marshall, R.; Li, J.; Zhang, Z.; Liu, J.; et al. Relationship between menopause and health-related quality of life in middle-aged Chinese women: A cross-sectional study. BMC Womens Health 2014, 14, 7.
4. Larroy, C.; Marin Martin, C.; Lopez-Picado, A.; Fernandez Arias, I. The impact of perimenopausal symptomatology, sociodemographic status and knowledge of menopause on women's quality of life. Arch. Gynecol. Obstet. 2020, 301, 1061-1068.
5. Moral, E.; Delgado, J.L.; Carmona, F.; Caballero, B.; Guillan, C.; Gonzalez, P.M.; Suarez-Almarza, J.; Velasco-Ortega, S.; Nieto, C. Genitourinary syndrome of menopause. Prevalence and quality of life in Spanish postmenopausal women. The GENISSE study. Climacteric 2018, 21, 167-173.
6. Nappi, R.E.; Lachowsky, M. Menopause and sexuality: Prevalence of symptoms and impact on quality of life. Maturitas 2009, 63, 138-141.
7. Pinkerton, J.V.; Abraham, L.; Bushmakin, A.G.; Cappelleri, J.C.; Komm, B.S. Relationship between changes in vasomotor symptoms and changes in menopause-specific quality of life and sleep parameters. Menopause 2016, 23, 1060-1066.
8. Wariso, B.A.; Guerrieri, G.M.; Thompson, K.; Koziol, D.E.; Haq, N.; Martinez, P.E.; Rubinow, D.R.; Schmidt, P.J. Depression during the menopause transition: Impact on quality of life, social adjustment, and disability. Arch. Womens Ment. Health 2017, 20, 273-282.
9. Mattioli, A.V.; Farinetti, A. Chocolate intake in pre-menopausal women. Atherosclerosis 2018, 269, 312.
10. Balboa-Castillo, T.; Lopez-Garcia, E.; Leon-Munoz, L.M.; Perez-Tasigchana, R.F.; Banegas, J.R.; Rodriguez-Artalejo, F.; Guallar-Castillon, P. Chocolate and health-related quality of life: A prospective study. PLoS ONE 2015, 10, e0123161.
11. Salonia, A.; Fabbri, F.; Zanni, G.; Scavini, M.; Fantini, G.V.; Briganti, A.; Naspro, R.; Parazzini, F.; Gori, E.; Rigatti, P.; et al. Chocolate and women's sexual health: An intriguing correlation. J. Sex. Med. 2006, 3, 476-482.
12. Radloff, L.S. The CES-D Scale: A Self-Report Depression Scale for Research in the General Population. Appl. Psychol. Meas. 1977, 1, 385-401.
13. Rose, N.; Koperski, S.; Golomb, B.A. Mood food: Chocolate and depressive symptoms in a cross-sectional analysis. Arch. Intern. Med. 2010, 170, 699-703.
14. Basu, A.; Schell, J.; Scofield, R.H. Dietary fruits and arthritis. Food Funct. 2018, 9, 70-77.
15. Sibona, M.; Destefanis, P.; Agnello, M.; Lillaz, B.; Giuliano, M.; Cai, T.; Gontero, P. The association of Boswellia resin extract and propolis derived polyphenols can improve quality of life in patients affected by prostatitis-like symptoms. Arch. Ital. Urol. Androl. Organo Uff. Soc. Ital. Ecogr. Urol. Nefrol. 2020, 91, 251-255.
16. Costa de Miranda, R.; Paiva, E.S.; Suter Correia Cadena, S.M.; Brandt, A.P.; Vilela, R.M. Polyphenol-Rich Foods Alleviate Pain and Ameliorate Quality of Life in Fibromyalgic Women. Int. J. Vitam. Nutr. Res. 2017, 87, 66-74.
17. Lopez-Garcia, E.; Guallar-Castillon, P.; Leon-Munoz, L.; Graciani, A.; Rodriguez-Artalejo, F. Coffee consumption and health-related quality of life. Clin. Nutr. 2014, 33, 143-149.
18. Davinelli, S.; Scapagnini, G.; Marzatico, F.; Nobile, V.; Ferrara, N.; Corbi, G. Influence of equol and resveratrol supplementation on health-related quality of life in menopausal women: A randomized, placebo-controlled study. Maturitas 2017, 96, 77-83.
19. Perez-Tasigchana, R.F.; Leon-Munoz, L.M.; Lopez-Garcia, E.; Banegas, J.R.; Rodriguez-Artalejo, F.; Guallar-Castillon, P. Mediterranean Diet and Health-Related Quality of Life in Two Cohorts of Community-Dwelling Older Adults. PLoS ONE 2016, 11, e0151596.
20. Utian, W.H. Quality of life (QOL) in menopause. Maturitas 2007, 57, 100-102.
21. Garcia-Yu, I.A.; Garcia-Ortiz, L.; Gomez-Marcos, M.A.; Alonso-Dominguez, R.; Gonzalez-Sanchez, J.; Mora-Simon, S.; Gonzalez-Manzano, S.; Rodriguez-Sanchez, E.; Maderuelo-Fernandez, J.A.; Recio-Rodriguez, J.I. Vascular and cognitive effects of cocoa-rich chocolate in postmenopausal women: A study protocol for a randomised clinical trial. BMJ Open 2018, 8, e024095.
22. Garcia-Yu, I.A.; Garcia-Ortiz, L.; Gomez-Marcos, M.A.; Rodriguez-Sanchez, E.; Agudo-Conde, C.; Gonzalez-Sanchez, J.; Maderuelo-Fernandez, J.A.; Recio-Rodriguez, J.I. Effects of Cocoa-Rich Chocolate on Blood Pressure, Cardiovascular Risk Factors, and Arterial Stiffness in Postmenopausal Women: A Randomized Clinical Trial. Nutrients 2020, 12, 1758.
23. Garcia-Yu, I.A.; Garcia-Ortiz, L.; Gomez-Marcos, M.A.; Rodriguez-Sanchez, E.; Lugones-Sanchez, C.; Maderuelo-Fernandez, J.A.; Recio-Rodriguez, J.I. Cocoa-rich chocolate and body composition in postmenopausal women. A randomized clinical trial. Br. J. Nutr. 2020, 1-23.
24. Grassi, D.; Desideri, G.; Necozione, S.; di Giosia, P.; Barnabei, R.; Allegaert, L.; Bernaert, H.; Ferri, C. Cocoa consumption dose-dependently improves flow-mediated dilation and arterial stiffness decreasing blood pressure in healthy individuals. J. Hypertens. 2015, 33, 294-303.
25. Epidat: Program for Epidemiological Data Analysis, Version 4.2; Consellería de Sanidade: Xunta de Galicia, Spain; Pan American Organization Health (PAHO-WHO), CES University: Medellín, Colombia, 2016.
26. EuroQol. A new facility for the measurement of health-related quality of life. Health Policy 1990, 16, 199-208.
27. Badia, X.; Roset, M.; Montserrat, S.; Herdman, M.; Segura, A. The Spanish version of EuroQol: A description and its applications. European Quality of Life scale. Med. Clin. (Barc) 1999, 1128 (Suppl. 1), 79-85.
28. Badia, X.; Roset, M.; Monserrat, S.; Herdman, M. The Spanish VAS tariff based on valuation of EQ-5D health states from the general population. In Proceedings of the EuroQol Plenary meeting, Rotterdam, The Netherlands, 2-3 October 1997; pp. 93-114.
29. Palacios, S.; Ferrer-Barriendos, J.; Parrilla, J.J.; Castelo-Branco, C.; Manubens, M.; Alberich, X.; Marti, A. [Health-related quality of life in the Spanish women through and beyond menopause. Development and validation of the Cervantes Scale]. Med. Clin. (Barc) 2004, 122, 205-211.
30. Lee, K.J.; Simpson, J.A. Introduction to multiple imputation for dealing with missing data. Respirology 2014, 19, 162-167.
31. White, I.R.; Royston, P.; Wood, A.M. Multiple imputation using chained equations: Issues and guidance for practice. Stat. Med. 2011, 30, 377-399.
32. Rubin, D. Multiple Imputation for Nonresponse in Surveys; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 1987.
33. Munguia, L.; Rubio-Gayosso, I.; Ramirez-Sanchez, I.; Ortiz, A.; Hidalgo, I.; Gonzalez, C.; Meaney, E.; Villarreal, F.; Najera, N.; Ceballos, G. High Flavonoid Cocoa Supplement Ameliorates Plasma Oxidative Stress and Inflammation Levels While Improving Mobility and Quality of Life in Older Subjects: A Double-Blind Randomized Clinical Trial. J. Gerontol. A Biol. Sci. Med. Sci. 2019, 74, 1620-1627.
34. Bruinsma, K.; Taren, D.L. Chocolate: Food or drug? J. Am. Diet. Assoc. 1999, 99, 1249-1256.
35. Meier, B.P.; Noll, S.W.; Molokwu, O.J. The sweet life: The effect of mindful chocolate consumption on mood. Appetite 2017, 108, 21-27.
36. Feng, Y.; Parkin, D.; Devlin, N.J. Assessing the performance of the EQ-VAS in the NHS PROMs programme. Qual. Life Res. 2014, 23, 977-989.
37. Scientific Opinion on the substantiation of a health claim related to cocoa flavanols and maintenance of normal endothelium-dependent vasodilation pursuant to Article 13(5) of Regulation (EC) No 1924/2006. EFSA J. 2012, 10, 2809.
38. Nurk, E.; Refsum, H.; Drevon, C.A.; Tell, G.S.; Nygaard, H.A.; Engedal, K.; Smith, A.D. Intake of flavonoid-rich wine, tea, and chocolate by elderly men and women is associated with better cognitive test performance. J. Nutr. 2009, 139, 120-127.
39. Llaneza, P.; Inarrea, J.; Gonzalez, C.; Alonso, A.; Arnott, I.; Ferrer-Barriendos, J. Differences in health related quality of life in a sample of Spanish menopausal women with and without obesity. Maturitas 2007, 58, 387-394.
40. Vladislavovna Doubova Dubova, S.; Flores-Hernandez, S.; Rodriguez-Aguilar, L.; Perez-Cuevas, R. Quality of care and health-related quality of life of climacteric stage women cared for in family medicine clinics in Mexico. Health Qual. Life Outcomes 2010, 8, 20.
41. Otero-Rodriguez, A.; Leon-Munoz, L.M.; Balboa-Castillo, T.; Banegas, J.R.; Rodriguez-Artalejo, F.; Guallar-Castillon, P. Change in health-related quality of life as a predictor of mortality in the older adults. Qual. Life Res. 2010, 19, 15-23.
42. Temple, J.L.; Bernard, C.; Lipshultz, S.E.; Czachor, J.D.; Westphal, J.A.; Mestre, M.A. The Safety of Ingested Caffeine: A Comprehensive Review. Front. Psychiatry 2017, 8, 80.
43. Franco, R.; Oñatibia-Astibia, A.; Martínez-Pinilla, E. Health benefits of methylxanthines in cacao and chocolate. Nutrients 2013, 5, 4159-4173.
44. Watson, E.J.; Coates, A.M.; Kohler, M.; Banks, S. Caffeine Consumption and Sleep Quality in Australian Adults. Nutrients 2016, 8, 479.
45. Moreno-Frías, C.; Figueroa-Vega, N.; Malacara, J.M. Relationship of sleep alterations with perimenopausal and postmenopausal symptoms. Menopause 2014, 21, 1017-1022.
46. Avis, N.E.; Crawford, S.L.; Greendale, G.; Bromberger, J.T.; Everson-Rose, S.A.; Gold, E.B.; Hess, R.; Joffe, H.; Kravitz, H.M.; Tepper, P.G.; et al. Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition. JAMA Intern. Med. 2015, 175, 531-539.
47. Thurston, R.C.; Joffe, H. Vasomotor symptoms and menopause: Findings from the Study of Women's Health across the Nation. Obstet. Gynecol. Clin. N. Am. 2011, 38, 489-501.
Irene A. Garcia-Yu1,*, Luis Garcia-Ortiz1,2, Manuel A. Gomez-Marcos1,3, Emiliano Rodriguez-Sanchez1,3, Olaya Tamayo-Morales1, Jose A. Maderuelo-Fernandez1,† and Jose I. Recio-Rodriguez1,4,†
1Instituto de Investigación Biomédica de Salamanca (IBSAL), Unidad de Investigación de Atención Primaria de Salamanca (APISAL), Servicio de Salud de Castilla y León (SACyL), 37005 Salamanca, Spain
2Departamento de Ciencias Biomédicas y del Diagnóstico, Universidad de Salamanca, 37007 Salamanca, Spain
3Departamento de Medicina, Universidad de Salamanca, 37007 Salamanca, Spain
4Departamento de Enfermería y Fisioterapia, Universidad de Salamanca, 37007 Salamanca, Spain
*Author to whom correspondence should be addressed.
†These authors contributed equally to this work.
© 2020. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Details
; Garcia-Ortiz, Luis; Gomez-Marcos, Manuel A
; Rodriguez-Sanchez, Emiliano; Tamayo-Morales, Olaya; Maderuelo-Fernandez, Jose A
; Recio-Rodriguez, Jose I